Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tomligisiran
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Tomligisiran is an investigational, liver-targeted **GalNAc-conjugated small interfering RNA** developed as one constituent of the fixed siRNA combination daplusiran + tomligisiran, formerly JNJ-3989 and ARO-HBV. It is designed to trigger RNA interference against hepatitis B virus X open reading frame messenger RNA in cccDNA-derived HBV transcripts, reducing viral RNA translation and thereby suppressing HBV protein production and replication. The daplusiran + tomligisiran combination is being evaluated by GSK in sequential treatment regimens with bepirovirsen for chronic hepatitis B. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-obtain-exclusive-license-for-jnj-3989/))
- Other names
- tomligisirantomligisiran sodium
02
Targets
HBx (Hepatitis B virus X protein)
Beyond the preview
Go deeper on tomligisiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tomligisiran.